A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 330

Inclusion Criteria

1. Male or female patients of at least 18 years of age
2. Patients with active acromegaly demonstrated by
• a lack of suppression of GH nadir to <1 µg/L after an oral tolerance test with 75 g of glucose (not applicable for diabetic patients) or a mean GH concentration of a 5-point profile within a 2 hour time period of > 5 µg/L
• elevated circulating IGF-1 concentration (age and sex adjusted)
3. a) Patients who have undergone one or more pituitary surgeries but have not been treated medically or b) de-novo patients who present with a visible pituitary adenoma on MRI and who refuse pituitary surgery or for whom pituitary surgery is contraindicated
4. Patients with a known history or new diagnisis of impaired fasting glucose or diabetes mellitus may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary (see Section 6.6.3)
5. Patients for whom written informed consent to participate in the study has been obtained. prior to any study related activity
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Patients who are being or were treated with octreotide, lanreotide or dopamine agonists or GH antagonists with the exception of a single dose of short-acting ocreotide or short-acting dopamine agonists. In case of a single dose of short-acting ocreotide, the dose should not be used to predict the response to the ocreotide treatment. The single dose of short acting ocreotide or short-acting dopamine agonists should not be administered in the 3 days prior to randomization.
2. De-novo patients having a visible adenoma on MRI
3. Patients who have received pasireotide prior to randomization
4. Patients with compression of the optic chiasm causing any visual field defect
5. Patients who require a surgical intervention for relief of any sign or symptom associated with tumor compression for whom surgical intervention is indicated
6. Patients who have undergone major surgery/surgical therapy for any cause within 1 month of visit 1
7. Patients who have received radiotherapy (except for pituitary irradiation) for any reason within 4 weeks of visit 1 must have recovered from any side effect of radiotherapy
8. Patients who have received pituitary irradiation within the last ten years prior to visit 1
9. Patients who are hypothyroid and not adequately treated with stable doses of thyroid hormone replacement therapy
10. Diabetic patients on antidiabetic medications whose fasting blood glucose is poorly controlled as evidenced by HbA1c >8%
11. Patients with symptomatic cholelithiasis
12. Patients with abnormal coagulation (PT and/or APTT elevated by 30% above normal limits) or patients receiving anticoagulants that affect PT (prothrombin time) or APTT (activated partial thromboplastin time)
13. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant
bradycardia, advanced heart block or a history of acute myocardial infarction within the 6 months preceding enrollment
14. Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTc > 450 ms, hypokalemia, hypomagnesemia, hypocalcemia, family history of long QT syndrome, and taking concomitant medications known to prolong QT interval
15. Patients with confirmed central hypothyroidism, central hypoadrenalism and diabetes insipidus, unless they are adequately treated with stable doses of hormone replacement therapy for a minimum of 3 months prior to study entry (first dose of study medication).Patients with confirmed central hypogonadism unless they are adequately treated with stable doses of hormone replacement therapy for a minimum of 3 months prior to study entry (first dose of study medication) except in cases where hormone replacement therapy is not indicated
16. Patients with liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or patients with ALT and/or AST more than 2 x ULN, serum creatinine > 2.0 x ULN, serum bilirubin > 2 x ULN, serum albumin < 0.67 x LLN
17. Patients with WBC <3 x 109/L; Hgb < 90%LLN; PLT <100 x 109/L
18. Patients who have any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the Investigator or the Sponsor’s Medical Monitor
19. Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control. Female patients must use barrier contraception w

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

safety and efficacy of pasireotide LAR versus octreotide LAR in patients with acromegaly

Phase 1

ovartis Pharma Services AG

Updated 6/20/2016

A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly - ND

OVARTIS FARMA

Updated 5/2/2016